Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Corporate Dr., 2 Nd Floor, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 488 % +19.1%
Debt-to-equity 73.1 % +75.5%
Return On Equity -111 % -27.8%
Return On Assets -63.9 % -4.62%
Operating Margin -2.66K %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 79.8M shares +83.4%
Entity Public Float 20.2M USD -42.6%
Common Stock, Value, Issued 8K USD
Weighted Average Number of Shares Outstanding, Basic 156M shares +262%
Weighted Average Number of Shares Outstanding, Diluted 157M shares +262%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.51M USD -75.3%
Research and Development Expense 75.6M USD +5.27%
General and Administrative Expense 25.9M USD -14%
Operating Income (Loss) -93.5M USD -10.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75.5M USD +7.28%
Income Tax Expense (Benefit) 212K USD -73.6%
Net Income (Loss) Attributable to Parent -75.7M USD +7.92%
Earnings Per Share, Basic -0.59 USD/shares +68.9%
Earnings Per Share, Diluted -0.59 USD/shares +68.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.1M USD -50.4%
Cash, Cash Equivalents, and Short-term Investments 94.5M USD +4.08%
Other Assets, Current 4.96M USD +47.6%
Assets, Current 99.6M USD +5.65%
Property, Plant and Equipment, Net 2.8M USD -29.2%
Operating Lease, Right-of-Use Asset 5.81M USD -20.5%
Other Assets, Noncurrent 631K USD +1.12%
Assets 109M USD +2.53%
Accounts Payable, Current 6.82M USD +110%
Employee-related Liabilities, Current 3.6M USD +14.7%
Accrued Liabilities, Current 12.1M USD -12.5%
Liabilities, Current 23.6M USD -13.4%
Operating Lease, Liability, Noncurrent 6.28M USD -30%
Other Liabilities, Noncurrent 133K USD -50.2%
Liabilities 41.6M USD +13.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 494K USD -0.6%
Retained Earnings (Accumulated Deficit) -517M USD -17.2%
Stockholders' Equity Attributable to Parent 67.2M USD -3.46%
Liabilities and Equity 109M USD +2.53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.7M USD -1.6%
Net Cash Provided by (Used in) Financing Activities -19K USD -1800%
Net Cash Provided by (Used in) Investing Activities -88.6M USD -543%
Common Stock, Shares Authorized 520M shares +62.5%
Common Stock, Shares, Issued 79.8M shares +83.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.1M USD -50.3%
Deferred Tax Assets, Valuation Allowance 34.2M USD -68.8%
Deferred Tax Assets, Gross 36.6M USD -67.5%
Operating Lease, Liability 10.9M USD -10.9%
Depreciation 1.29M USD -31.7%
Payments to Acquire Property, Plant, and Equipment 7K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.7M USD +7.42%
Lessee, Operating Lease, Liability, to be Paid 12.6M USD -14.8%
Property, Plant and Equipment, Gross 14.1M USD -2%
Operating Lease, Liability, Current 3.35M USD +5.61%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.68M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD +4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -11.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.75M USD -33.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.8M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 99K USD -96.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.44M USD -59.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.38M USD -25%
Share-based Payment Arrangement, Expense 2.06M USD -35.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%